QGEN Stock Falls -18% In 10-day Spree On Zacks Downgrade To Strong Sell
Qiagen (QGEN) – a provider of molecular biology consumables and diagnostic assays – hit a 10-day losing streak, with cumulative losses over this period amounting to -18%. The company’s market cap has crashed by about $2.0 Bil over the last 10 days and currently stands at $8.8 Bil.
The stock has YTD (year-to-date) return of 9.9% compared to -1% for S&P 500. This calls for a re-evaluation of the stock’s valuation to find out whether this is an opportunity or a trap.
What Triggered The Slide?
[1] Zacks Downgrade and EPS Estimate Cut
- Zacks Research downgraded QGEN from a “hold” to a “strong sell”
- Zacks lowered its Q1 2026 EPS forecast to $0.56 from $0.61
- Impact: Sustained institutional selling, Negative investor sentiment
[2] Significant Increase in Short Interest
- Short interest increased by 20.0% to 7.18 million shares as of February 13th
- Represents approximately 3.7% of the company’s shares being shorted
- Impact: Heightened bearish market perception, Increased selling pressure
Opportunity or Trap?
Below is our take on valuation.
There are only a couple of things to fear in QGEN stock given its overall Strong operating performance and financial condition. Considering stock’s Moderate valuation, we think it is Attractive (For details, see Buy or Sell QGEN).
But here is the real interesting point.
You are reading about this -18% move after it happened. The market has already priced in the news. To avoid the next loser before the headlines, you need predictive signals, not notifications. Our High Quality Portfolio has a risk model designed to reduce exposure to losers.
Returns vs S&P 500
The following table summarizes the return for QGEN stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | QGEN | S&P 500 |
|---|---|---|
| 1D | -1.3% | 0.0% |
| 10D (Current Streak) | -18.5% | -1.5% |
| 1M (21D) | -20.5% | -2.4% |
| 3M (63D) | -11.2% | -1.6% |
| YTD 2026 | -9.9% | -1.0% |
| 2025 | 1.5% | 16.4% |
| 2024 | 5.5% | 23.3% |
| 2023 | -12.9% | 24.2% |
Gains and Losses Streaks: S&P 500 Constituents
There are currently 21.0 S&P constituents with 3 days or more of consecutive gains and 121 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 21 | 44 |
| 4D | 0 | 30 |
| 5D | 0 | 16 |
| 6D | 0 | 9 |
| 7D or more | 0 | 22 |
| Total >=3 D | 21 | 121 |
Key Financials for Qiagen (QGEN)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $2.0 Bil | $2.0 Bil |
| Operating Income | $445.2 Mil | $199.9 Mil |
| Net Income | $341.3 Mil | $83.6 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ2 | 2025 FQ3 |
|---|---|---|
| Revenues | $533.5 Mil | $532.6 Mil |
| Operating Income | $136.0 Mil | $137.3 Mil |
| Net Income | $96.2 Mil | $130.0 Mil |
The losing streak QGEN stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.